Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-053778
Filing Date
2025-04-14
Accepted
2025-04-14 17:10:22
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9804
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 15707
3 EX-99.B ck0001669811-ex99_b.pdf EX-99.B 10500
  Complete submission text file 0000950170-25-053778.txt   48006
Mailing Address 1900 N. PEARL STREET, 20TH FLOOR DALLAS TX 75201
Business Address 1900 N. PEARL STREET, 20TH FLOOR DALLAS TX 75201 214.880.4050
MAVERICK CAPITAL LTD (Filed by) CIK: 0000934639 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX
Type: SCHEDULE 13G

Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Subject) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88750 | Film No.: 25836711
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)